Specimen Collection Cards Market to Reach USD 715.4 Million by 2035 as Personalized Medicine and Newborn Screening Programs Drive Global Demand

The global Specimen Collection Cards Market is witnessing steady growth as healthcare systems increasingly adopt decentralized diagnostics, genetic testing, and newborn screening programs. Specimen collection cards have become indispensable tools for collecting, preserving, transporting, and storing biological samples while maintaining sample integrity for accurate laboratory analysis.

According to the latest market analysis, the global Specimen Collection Cards Market was valued at US$ 441.5 Million in 2024 and is projected to reach US$ 715.4 Million by 2035, expanding at a CAGR of 4.5% from 2025 to 2035.

The growing demand for personalized medicine, expanding genetic testing applications, increasing prevalence of chronic diseases, and widespread implementation of newborn screening initiatives are among the primary factors supporting market expansion. Furthermore, technological innovations in dried blood spot (DBS) collection technologies, microsampling solutions, and specimen preservation materials are improving diagnostic accuracy while enabling convenient sample collection outside traditional healthcare facilities.

As healthcare providers continue emphasizing early disease detection, precision medicine, and remote diagnostics, specimen collection cards are expected to play an increasingly important role in modern laboratory workflows.

→Discover Market Opportunities - Request Your Sample Copy Now: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=86803

Personalized Medicine and Genetic Testing Drive Market Growth

One of the strongest growth drivers for the Specimen Collection Cards Market is the rapid expansion of personalized medicine and genetic testing.

Healthcare providers are increasingly utilizing genomic information to develop individualized treatment strategies tailored to each patient's genetic profile. This growing adoption of precision medicine requires reliable specimen collection systems capable of preserving DNA, RNA, proteins, and other biological markers for advanced molecular testing.

Specimen collection cards provide a simple, minimally invasive solution for collecting biological samples while maintaining sample quality throughout transportation and storage. Their ability to preserve nucleic acids under controlled conditions makes them particularly valuable for genomic research, pharmacogenomics, oncology diagnostics, inherited disease screening, and population health studies.

Compared with traditional liquid specimen collection methods, collection cards simplify logistics, reduce transportation costs, minimize contamination risks, and improve sample stability.

The increasing use of decentralized genetic testing and home-based sample collection is further accelerating demand for high-quality specimen collection cards across clinical laboratories, research institutions, pharmaceutical companies, and healthcare providers worldwide.

Expanding Newborn Screening Programs Accelerate Adoption

Government-supported newborn screening initiatives represent another major contributor to market growth.

Dried blood spot (DBS) collection cards have become the global standard for newborn screening because they allow rapid, minimally invasive blood collection shortly after birth.

These cards enable laboratories to screen infants for numerous inherited metabolic disorders, endocrine abnormalities, genetic diseases, hemoglobinopathies, and other life-threatening conditions before symptoms appear.

Early diagnosis allows healthcare providers to initiate timely treatment, significantly improving long-term patient outcomes while reducing healthcare costs associated with delayed diagnosis.

Many countries continue expanding mandatory newborn screening programs by adding additional disorders to national screening panels.

As hospital birth rates remain high and governments invest further in preventive healthcare programs, demand for standardized specimen collection cards continues increasing globally.

Improved laboratory infrastructure and greater awareness regarding early disease detection are expected to further strengthen adoption throughout the forecast period.

Decentralized Diagnostics and Remote Healthcare Expand Market Opportunities

The growing shift toward decentralized healthcare represents a significant opportunity for the Specimen Collection Cards Market.

Healthcare providers increasingly perform diagnostic testing outside traditional hospital laboratories through community healthcare centers, physician offices, home healthcare programs, pharmacies, and mobile diagnostic services.

Specimen collection cards facilitate this transition by allowing biological samples to be collected remotely and transported safely to centralized laboratories for analysis.

Unlike conventional liquid samples requiring cold-chain transportation, many dried specimen collection cards remain stable at ambient temperatures, reducing logistical complexity and transportation expenses.

These advantages make specimen collection cards particularly valuable in rural healthcare settings, low-resource regions, epidemiological surveillance programs, clinical research studies, infectious disease monitoring, and global public health initiatives.

Growing acceptance of telemedicine and home-based diagnostic services further increases demand for reliable specimen collection technologies capable of supporting remote testing workflows.

Technological Advancements Improve Diagnostic Performance

Continuous technological innovation is enhancing the performance and versatility of specimen collection cards.

Manufacturers are introducing advanced materials that improve sample preservation, reduce contamination, increase analyte stability, and enhance compatibility with modern laboratory instruments.

Innovations in microsampling technologies now enable more precise collection of extremely small specimen volumes while maintaining analytical accuracy.

Advanced fiber-based collection materials, specialized preservation chemistries, and automated sample processing technologies continue improving laboratory efficiency and diagnostic reliability.

Modern specimen collection cards support a wide range of laboratory applications including molecular diagnostics, polymerase chain reaction (PCR), next-generation sequencing (NGS), therapeutic drug monitoring, infectious disease detection, forensic investigations, toxicology testing, and biomarker discovery.

These technological improvements continue expanding the clinical applications of specimen collection cards while supporting greater laboratory automation.

→Explore Strategies & Trends - Request Full Report Access – https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=86803

Blood Specimen Collection Cards Dominate the Market

Based on specimen type, blood specimen collection cards accounted for approximately 85.4% of global market revenue in 2024, making them the dominant segment.

Blood remains the preferred biological specimen because it contains numerous clinically relevant biomarkers including DNA, RNA, proteins, metabolites, antibodies, hormones, and various cellular components required for comprehensive laboratory analysis.

Dried blood spot (DBS) collection cards have become widely adopted across newborn screening, infectious disease surveillance, therapeutic drug monitoring, clinical research, and forensic testing.

Their popularity is driven by several advantages, including simple collection procedures, reduced biohazard risks, minimal sample volume requirements, long-term storage capability, and lower transportation costs.

Blood collection cards also support decentralized testing by allowing samples to be collected in remote locations before being transported safely to centralized laboratories.

As molecular diagnostics continue expanding worldwide, blood-based specimen collection cards are expected to maintain their dominant market position throughout the forecast period.

North America Leads the Global Specimen Collection Cards Market

North America remains the leading regional market, accounting for approximately 40.6% of global revenue in 2024.

The region benefits from highly developed healthcare infrastructure, advanced diagnostic laboratories, well-established newborn screening programs, and widespread adoption of precision medicine.

Strong government support for early disease detection, expanding genomic research, and increasing healthcare expenditure continue driving market growth throughout the United States and Canada.

Regulatory standards governing laboratory quality and specimen handling further encourage adoption of standardized specimen collection solutions.

The region also hosts many leading biotechnology companies, diagnostic manufacturers, pharmaceutical organizations, and research institutions actively investing in molecular diagnostics and personalized medicine.

Meanwhile, Europe continues experiencing steady growth due to expanding genetic testing initiatives and advanced public healthcare systems, while Asia-Pacific is expected to register significant future growth owing to increasing healthcare investments, expanding newborn screening coverage, rising chronic disease prevalence, and improving diagnostic infrastructure.

Competitive Landscape

The global Specimen Collection Cards Market is moderately competitive, with leading manufacturers focusing on product innovation, strategic acquisitions, geographic expansion, and partnerships with healthcare providers and diagnostic laboratories.

Major companies operating in the market include QIAGEN, PerkinElmer, Hemaxis, Danaher Corporation, Eastern Business Forms, Inc., Thermo Fisher Scientific Inc., GenTegra LLC., CENTOGENE GmbH, ARCHIMEDlife GmbH, FortiusBio, Ahlstrom, genetechinnovations, EUROIMMUN Medizinische Labordiagnostika AG, F. Hoffmann-La Roche AG., and Capitainer.

These companies continue investing in advanced specimen preservation technologies, high-performance collection materials, laboratory automation, and integrated diagnostic solutions to strengthen their competitive positions.

Strategic collaborations with research institutions, healthcare organizations, and biotechnology companies remain important growth strategies across the industry.

Recent Industry Developments

Several recent developments continue shaping the Specimen Collection Cards Market.

In October 2025, Ahlstrom acquired Eastern Business Forms (EBF), significantly expanding its life sciences portfolio and strengthening its capabilities in manufacturing natural fiber-based specimen collection cards for biological sample preservation.

Earlier, in February 2023, Capitainer AB introduced an advanced self-sampling solution capable of collecting approximately five times more blood than its previous product generation, improving sample collection efficiency for decentralized diagnostic applications.

These innovations demonstrate the industry's continued focus on improving specimen quality, expanding self-collection capabilities, and supporting broader adoption of remote healthcare services.

Future Outlook

The future of the global Specimen Collection Cards Market remains promising as healthcare systems increasingly prioritize early disease detection, precision medicine, decentralized diagnostics, and efficient laboratory workflows.

Growing investments in genomic medicine, expanding newborn screening programs, rising infectious disease surveillance, and continuous technological advancements are expected to create sustained demand for advanced specimen collection solutions.

Future innovations involving improved preservation materials, automated laboratory integration, microsampling technologies, and compatibility with next-generation molecular diagnostics will further enhance market opportunities.

As personalized healthcare becomes increasingly integrated into routine clinical practice, specimen collection cards will remain essential tools supporting accurate, efficient, and accessible diagnostic testing worldwide through 2035.

Buy Full Report Now: https://www.transparencymarketresearch.com/checkout.php?rep_id=86803<ype=S

→Explore Latest Research Reports by Transparency Market Research:

Autoimmune Disease Diagnostics Market

In Vitro Diagnostics Market

Non-Invasive Cancer Diagnostics Market

Multiplexed Diagnostics Market

Point-of-Care Diagnostics Market

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Media Contact: 

Abhishek Budholiya

Transparency Market Research Inc.

State Tower, 90 State Street, Suite 700,

Albany NY - 12207, United States

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com 

Sales Inquiries: sales@transparencymarketresearch.com

Media Inquiries: media@transparencymarketresearch.com